triumph 1 retatrutide produces up to 30.3% weight loss in Phase 3 trial retatrutide 3 months A summary

Conservative guidance suggests avoiding BPC-157 with any cancer history pending better safety data

For example, degradation of PYY (136) to the more potent gastric inhibitor PYY (336) is prevented by DPP-4 inhibition.50 Clinical implications Glucose control A complex interaction exists between glycaemia and gastric motility.51 Higher glucose levels delay, whereas lower levels stimulate gastric emptying.5254 As a result, the inhibitory effect of GLP-1 on gastric emptying is more pronounced during hyperglycaemia and reduced during hypoglycaemia.52 ,53 Conversely, gastric emptying rate is accountable for approximately 35% of the postprandial glucose excursions.55 ,56 Consequently, inhibition of gastric emptying by GLP-1 and short-acting GLP-1RAs reduces postprandial glucose levels.34 ,57 The significance of this effect was demonstrated in a study where co-infusion of the prokinetic erythromycin blunted the inhibiting effect of GLP-1 infusion on postprandial glucose excursions.58 Weight loss While DPP-4Is are weight-neutral, GLP-1RAs (short-acting and long-acting) induce weight loss in a dose-dependent manner.59 Recently, a high-dose preparation of the long-acting GLP-1RA liraglutide (3.0 mg) has been approved for weight reduction.60 Mechanisms underlying this weight loss are still incompletely understood

It improves expressive and receptive language, imitation, social skills, eating, sleeping, toileting, and moreall while reducing problem behaviors

Tamoxifen was included in the standard of care for long-term adjuvant therapy for estrogen receptor-positive breast cancer (Krishnamurthy et al., 2022)